FoxO1/FKHR Antibody – Pre-diluted Summary
Synthetic peptide corresponding to internal region of human FOXO1A.
This product is specific for FOXO1A
IgG
Polyclonal
Rabbit
FOXO1
Immunogen affinity purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
Applications/Dilutions
- Immunohistochemistry 1:10-1:500
- Immunohistochemistry-Paraffin Neat
IHC-P: Working dilution, ready to use for 10 minutes at RT. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0 for 10 minutes followed by cooling at RT for 20 minutes. Ab15538 demonstrates cytoplasmic staining. Not tested in other applications. Optimal dilutions/concentrations should be determined by the end user.
Reactivity Notes
This product is specific for Human.
Packaging, Storage & Formulations
Store at 4C. Do not freeze.
Prediluted antibody
No Preservative
Immunogen affinity purified
Alternate Names for FoxO1/FKHR Antibody – Pre-diluted
- FKH1
- FKHR
- FKHRforkhead box protein O1
- forkhead box O1
- Forkhead box protein O1A
- forkhead homolog in rhabdomyosarcoma
- Forkhead in rhabdomyosarcoma
- FoxO1
- FOXO1Aforkhead, Drosophila, homolog of, in rhabdomyosarcoma
Background
FKHR (FoxO1), a member of the FoxO subfamily of forkhead transcription factors, is an important target for insulin and growth factor signaling in the regulation of metabolism, cell cycle and proliferation, and survival in peripheral tissues (1). FKHR is regulated by insulin via Akt-dependent phosphorylation and nuclear exclusion. It has been shown that FoxO1 is induced in the early stages of adipocyte differentiation but that its activation is delayed until the end of the clonal expansion phase. Constitutively active FoxO1 prevents the differentiation of preadipocytes, while dominant-negative Foxo1 restores adipocyte differentiation of fibroblasts from insulin receptor-deficient mice (2). Conserved residue (Ser329) is a novel in-vivo phosphorylation site on FKHR. Phosphorylation of this site also decreases the ability of FKHR to stimulate gene transactivation and reduces the proportion of FKHR present in the nucleus (3)
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.